Engineering The Future Of Genetic Medicine

Progress, Potential, and Possibilities – Benjamin Oakes, co-founder and CEO of Scribe Therapeutics, joins the podcast for a discussion on designing a better tomorrow.

Leadership essentials: “Inspire, motivate, and cultivate”

Big Think – Benjamin Oakes — CEO of buzz-worthy biotech company Scribe Therapeutics — joins Big Think for a chat about innovation, human endeavor, and more.

Small Enzymes, Giant Leaps: CRISPR’s Next-Generation Approach to Genetic Diseases

BioSpace – The company is pioneering a data-driven engineering approach—CRISPR by Design—that enables Scribe to build systems that allow for different genome editing outcomes than what’s possible with Cas9.

Future of Epigenetic Medicine

FutureBites Podcast – Today’s guest on FutureBites is Dr. Ben Oakes, Co-founder, President and CEO of Scribe Therapeutics, a company that’s focused on designing and applying CRISPR-derived tools that not only edit genes directly and permanently, but also control and fine tune the conditions that decide whether a gene is turned on or off.

CRISPR 2.0, the Next Generation

Aspen Ideas: Health – With dozens of CRISPR therapeutics in the second phase of human trials, hopes run high that next-generation approaches will be easier and cheaper to deliver and more patient friendly.

CRISPR technology’s next wave: Eight companies to watch in 2024

Labiotech – Scribe Therapeutics leverages its CRISPR by design platform, which includes custom-engineered CRISPR enzymes.

Top Five Privately Held Gene Editing Therapy Companies

Genetic Engineering & Biotechnology News – Scribe Therapeutics has attracted $120 million in venture capital and $140 million in upfront payments from biopharma partners.

Women @ RopesTalk: Conversation with Svetlana Lucas, Scribe Therapeutics

Women @ RopesTalk Podcast – Svetlana Lucas, PhD, shares her journey in the biotech industry, the challenges and opportunities she has encountered, and her insights on the future of CRISPR technology. She also discusses the importance of relationships, diversity, and mentorship in the industry, and embracing the concept of “being comfortable with being uncomfortable.”

DNA: Cutting the Future of Genome Editing

The Biomedical Scientist – Biotechnology company Scribe Therapeutics builds CRISPR, genome-editing and other types of genetic modification technologies for different conditions, including cardiometabolic disease.

CRISPR technologies fuelling haematological innovations

European Pharmaceutical Review – GlobalData highlighted that the largest CRISPR-based deal of 2023 was Eli Lily’s subsidiary, Prevail Therapeutics gaining rights to Scribe Therapeutics’s CRISPR X-Editing (XE) technologies. In a deal potentially worth over $1.57 billion, the agreement seeks to advance in vivo therapies for targets that cause serious neurological and neuromuscular diseases.

CRISPR drug licensing deals secure $21bn in top three therapy areas over five years

Pharmaceutical Technology – Concurrently, Sanofi expanded its collaboration with Scribe in July 2023, with a deal worth up to $1.24bn, focusing on leveraging Scribe’s XE genome editing technologies for the development of in vivo therapies, particularly sickle cell disease and other genomic disorders.

Benjamin Oakes and the Promise of CRISPR

Sounds of Science – Benjamin Oakes, scientist, entrepreneur, and co-founder of Scribe Therapeutics, appears on Eureka’s Sounds of Science to discuss his personal vision for the future of CRISPR, encouraging advances in the field, and the first ever drug approval for a CRISPR based therapy.

CRISPR by Design with Benjamin Oakes

Raising Health – Scribe Therapeutics cofounder and CEO Benjamin Oakes, PhD, joins a16z Bio + Health founding general partner Vijay Pande on a16z Bio + Health podcast Raising Health.

CRISPR Partnerships Propel Precision Medicine

CRISPR Medicine News – Meanwhile, the high-risk bone marrow ablation required for diseases like sickle cell disease and beta-thalassemia is driving innovation towards in vivo genome editing, with companies like Scribe Therapeutics and Sanofi embarking on a $1.24 billion venture to develop more precise and deliverable Cas endonucleases.

A CRISPR collaboration compilation

Nature Biopharma Dealmakers – Major biopharma companies are partnering with pioneers of genome-editing technologies to realize the potential of this emerging precision medicine modality.

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

Scrip – Scribe Therapeutics is one of a new generation of CRISPR-based gene-editing companies, and believes its in vivo CRISPR X-Editing (XE) technology could be the most efficient yet.

A road to survival

ASBMB Today – Outside of academia, companies including Scribe Therapeutics are also developing gene therapies for diseases such as sickle cell.

Peer Review

Endpoints News – The California-based CRISPR biotech has tapped Aarif Khakoo as CSO and head of R&D, and appointed Maria Mirotsou as VP of discovery biology.

FDA approves CRISPR–Cas9 therapy for sickle cell disease

ASBMB Today – Benjamin Oakes, CEO and cofounder of Scribe Therapeutics, said “The approval is just the tip of the iceberg. It’s a really beautiful proof of concept for what CRISPR genome editing can do. … The real vision and mission for the whole CRISPR field should be to create safer, more effective therapies that can be brought more broadly to patients.”

A decade later, biotech’s CRISPR revolution is still going strong

BioPharma Dive – “Large pharma is recognizing that this has the potential to be the future of medicine,” said Benjamin Oakes, co-founder and CEO of Scribe Therapeutics, an early-stage CRISPR drug developer now working with Eli Lilly and Sanofi.

Influential Women 2023: Svetlana Lucas, Chief Business Officer, Scribe Therapeutics

San Francisco Business Times – Interview with Svetlana Lucas, one of the outstanding professionals in the 2023 class of Most Influential Women in Bay Area Business.

Scribe Therapeutics’ Gene-Editing Tech Attracts Pharma Partners

The Wall Street Journal – Drugmakers are doubling down on deals with genome-editing startup Scribe Therapeutics, which could earn more than $2 billion through its newly expanded collaboration with Sanofi.

Sanofi expands collaboration with Scribe on CRISPR genome editing

Seeking Alpha – Sanofi is receiving an exclusive license for privately held Scribe Therapeutics’ CRISPR X-Editing genome editing technologies to develop in vivo therapies.

Scribe Therapeutics and Sanofi collaborate on in vivo therapies for sickle cell disease

BioWorld – Scribe Therapeutics Inc. has announced an expanded collaboration with Sanofi SA, under which Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo therapies, including for sickle cell disease.

Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure

STAT – Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

East Bay’s Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease

San Francisco Business Times – It is the second potential multibillion-dollar deal between Alameda’s Scribe Therapeutics Inc. and Sanofi (NASDAQ: SNY) around the East Bay company’s technologies to make precise edits to cells.

Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond

Fierce Biotech – Less than a year since partnering up for the first time, Sanofi and Scribe are at it again, this time working together on new in vivo therapies in a deal that could see the Jennifer Doudna-founded biotech in line for over $1.2 billion.

Sanofi expands research deal with gene editing startup Scribe

BioPharma Dive – Under the new deal, Sanofi gets to use Scribe’s CRISPR-based gene editing technology to develop in vivo therapies as well.

Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact

Endpoints News – Sanofi has inked another collaboration with its CRISPR partner Scribe Therapeutics as the duo seeks to create a newer, safer approach to tackling sickle cell disease.

Sanofi goes back to Scribe

Evaluate Vantage – The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.

Sanofi and Scribe’s expanded deal builds path to in vivo editing in SCD

BioCentury –Scribe CEO Benjamin Oakes told BioCentury the next-generation nuclease company had been seeking a partner with non-viral, extra-hepatic delivery vectors, and found it in Sanofi, with which it was already collaborating on NK cell therapies for cancer.

Scribe Inks CRISPR Gene-Editing Deal with Prevail

Bloomberg Technology – CRISPR pioneer Jennifer Doudna’s company Scribe Therapeutics inked a major deal with Prevail Therapeutics potentially worth $1.5 billion to create genetic medicines for neurological and neuromuscular diseases. Scribe CEO Ben Oakes joins Caroline Hyde for more.

Scribe signs another big pharma deal

Evaluate Vantage – Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.

Lilly’s Prevail, Doudna’s Scribe Partner on Genetic Treatments for Neuro Diseases

BioSpace – At the core of the research collaboration are Scribe’s proprietary X-editing (XE) technologies, which allow the company to develop in vivo treatments with three key attributes: deliverability, specificity and greater editing activity.

Scribe and Prevail to accelerate CRISPR-based genetic medicines for neurological and neuromuscular diseases

Labiotech – The deal gives Prevail exclusive rights to Scribe Therapeutics’ CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.

Scribe and Prevail partner for CRISPR-based genetic medicines

Pharmaceutical Technology – The deal will see the integration of Scribe’s new CRISPR by Design approach and Prevail’s expertise in developing genetic medicines for neurological disorders for specific genetic targets.

Scribe pens $1.5B-plus CRISPR tech deal with Lilly

BioWorld – Scribe Therapeutics Inc. is selling exclusive rights to its CRISPR-based technology to Prevail Therapeutics Inc. for a figure that could top $1.6 billion as the firms team up to develop genetic therapies for serious neurological and neuromuscular diseases.

Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal

San Francisco Business Times – Calling it “CRISPR by Design,” Scribe says those tools allow cuts to be made in our bodies, rather than engineered outside the body and infused inside humans.

Biotech Scribe strikes gene editing deal with Lilly subsidiary

BioPharma Dive – Scribe’s partnership with New York-based Prevail is its biggest deal yet. Attached to the deal is $1.5 billion in “biobucks,” payments to Scribe contingent on research under the collaboration hitting certain milestones.

Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal

Seeking Alpha – Scribe Therapeutics is collaborating with Eli Lilly’s unit (NYSE:LLY) Prevail Therapeutics and granted rights to its CRISPR X-Editing (XE) technologies to develop in vivo therapies for neurological and neuromuscular diseases.

Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration

Genetic Engineering & Biotechnology News – Through its subsidiary Prevail, Lilly is the third biopharma giant to partner with Scribe on developing CRISPR-based therapies.

Scribe’s CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit

Fierce Biotech – Eli Lilly’s Prevail Therapeutics is jotting down up to $1.5 billion for Scribe Therapeutics in hopes of writing some new CRISPR-based genetic medicines for neurological and neuromuscular diseases into history.

The New Age of CRISPR

I am BIO Podcast – CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. This episode features scientists working to push these gene editing tools to the next frontier.

Industry appetite for natural killer cells intensifies

Nature Biotechnology – Sanofi also turned to Scribe Therapeutics’ CRISPR platform to develop off-the shelf NK cell therapies for oncology, paying $25 million up front in a deal that could be worth $1 billion.

Economic Forecast 2023

San Francisco Business Times – Tapping the power of the CRISPR genome-editing technology, Alameda-based Scribe Therapeutics recently signed a deal with drug maker Sanofi to enable genetic modification of novel “natural killer” cell therapies for cancer.

Building a biotech in a downturn: 3 lessons from VCs and startup CEOs

BioPharma Dive – Read three takeaways from a panel hosted by BioPharma Dive featuring Scribe Therapeutics CEO Benjamin Oakes.

Deals In Depth: September 2022

In Vivo – In September, Sanofi received non-exclusive rights to use Scribe Therapeutics, Inc.’s proprietary CRISPR genome editing technologies and platform of wholly owned enzymes to create ex vivo natural killer cell therapies for cancer.

Follow the Money

Bio-IT World – The agreement grants Sanofi non-exclusive rights to Scribe’s proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies.

Scribe and Sanofi partner to develop cell therapies for cancer

Pharmaceutical Technology – Scribe’s CasX-Editors (XE), a suite of custom engineering genome editing and delivery tools based on new foundations such as the CasX enzyme, will back Sanofi’s developing NK cell therapies pipeline for cancer.

Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

Scrip – Sanofi is turning to gene-editing pioneer Jennifer Doudna and her CRISPR-CasX-based Scribe Therapeutics, Inc. to help it take its next steps in developing potential off-the-shelf cancer therapeutics derived from engineered natural killer (NK) cells.

Scribe, Vertex add to gene therapy’s advance with $1B+ deal, near-term BLA

BioWorld – Venture-backed startup Scribe Therapeutics Inc. landed a $25 million up-front payment and a chance at more than $1 billion in milestones by granting Sanofi SA license to genome-editing technology for multiple oncology targets.

Sanofi’s NK cell toolbox grows with Scribe’s next-gen editor

BioCentury – Scribe Therapeutics Inc. said Tuesday it will grant Sanofi non-exclusive rights to its CasX-Editor technology for multiple undisclosed oncology targets in engineered NK cell therapies.

Natural killers gain more attention with major Franco-US collab

The Pharma Letter – Californian genetic medicine company Scribe Therapeutics has scored a major strategic collaboration with French giant Sanofi.

Sanofi, Scribe Launch Up-to-$1B CRISPR-Based Cancer NK Cell Therapy Collaboration

Genetic Engineering and Biotechnology News – Sanofi and Scribe Therapeutics will partner to develop CRISPR-based cell therapies to fight cancer, the companies said today, through a collaboration that could generate more than $1 billion for the CRISPR drug developer whose co-founders include Nobel laureate Jennifer Doudna, PhD, of UC Berkeley.

Sanofi partners with Scribe to gain gene editing tools for cell therapy work

BioPharma Dive – Sanofi will partner with the Californian biotechnology company Scribe Therapeutics in a deal that extends its exploration of new ways to build cancer cell therapies.

Sanofi turns to startup Scribe to CRISPR edit new NK cell therapies for cancer

MedCity News – Sanofi is collaborating with Scribe Therapeutics to use the startup’s CRISPR technology to create cell therapies based on natural killers, a type of immune cell that has cancer-killing capabilities.

Sanofi to utilise Scribe’s CRISPR platform to develop cancer cell therapies

FirstWord Pharma – Sanofi entered into an agreement to use Scribe Therapeutics’ CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer.

Sanofi and Jennifer Doudna-Founded Scribe Ink $1B CRISPR Cell Therapy Deal

BioSpace – Under the terms of the deal, Sanofi picks up non-exclusive rights to Scribe’s CRISPR platform of wholly owned enzymes.

Sanofi pays Scribe $25M to access CRISPR tools, writing new chapter in its NK cell therapy story

Fierce Biotech – Sanofi has teamed up with Scribe Therapeutics to write the next chapter in its natural killer (NK) cell therapy story, paying $25 million upfront and committing to $1 billion in biobucks for access to a CRISPR platform.

Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance

Endpoints News – The Paris-based giant’s head of oncology research and its chief of genomic medicine have settled on Scribe Therapeutics’ CasX editing tech for their work on NK cells.

CEO of Doudna spinout: Within five years, genome editors will have a ‘really big impact’ on patients’ lives

Endpoints News – “CRISPR-by-design” is the idea behind Scribe Therapeutics, a company spun out from Jennifer Doudna’s Nobel-winning lab that’s competing in a closely-tracked field of genome editor companies just starting to make their way to the clinic.

Scribe Therapeutics converting an Alameda shipway into a lab

The Real Deal – Scribe Therapeutics, a molecular engineering company, is the latest notable lessee after securing a building at the Research Park at Marina Village in Alameda.

How Jennifer Doudna’s Life Has Changed Since Discovering CRISPR 10 Years Ago

TIME – [Ben Oakes’] team has pioneered a CRISPR system relying on a different enzyme, or DNA-cutting molecule, than the original CRISPR platform, and in animal models of ALS, the system seems to edit the targeted mutations more efficiently and contribute to a longer lifespan for the animals than the original CRISPR platform.

Innovators Under 35 2022

MIT Technology Review – As CEO of Scribe Therapeutics, Benjamin Oakes, 33, is working to optimize novel CRISPR enzymes and ways to package the gene-editing systems to solve those problems.

Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration

Genetic Engineering and Biotechnology News – CEO Benjamin Oakes recently discussed the Biogen collaboration, and his company’s progress in developing its genome editing technology, in an exclusive interview with GEN Edge.

Biogen Pursues Another Neuro Target With Scribe

Inside Precision Medicine – Biogen has exercised an option for an additional disease target in gene therapy with Scribe Therapeutics. This is part of the companies’ ongoing research collaboration to develop and commercialize CRISPR-based therapeutics.

Scribe, Biogen expand ALS CRISPR agreement

Pharma Manufacturing – Scribe, headquartered outside of San Francisco, focuses on creating gene therapies using CRISPR technology and custom engineered enzymes. The company’s custom platforms help it to overcome the technological hurdles that other companies in the field face, said Oakes.

Biogen takes another dip into Scribe gene therapy collab with another disease target

Fierce Biotech – Biogen is double-dipping into a 2020 collaboration with Scribe Therapeutics, exercising its option for an additional neurological disease target in gene therapy using the biotech’s CRISPR technology.

Biogen, Scribe to develop additional gene therapy disease target

Seeking Alpha – Biogen (NASDAQ:BIIB) has exercised an option to develop another gene therapy disease target as part of a collaboration with Scribe Therapeutics.

40 Under 40: Benjamin Oakes, Scribe Therapeutics

San Francisco Business Times – Scribe Therapeutics CEO Benjamin Oakes is honored in the San Francisco Business Times’ 40 Under 40 Class of 2022.

Future of Genetic Medicine w/ Scribe Therapeutics Founders

BIOS Podcast – An interview with Scribe co-founders Ben Oakes and Dave Savage on the future of genetic medicine.

The Science of CRISPR with Dr. Benjamin Oakes

Science in Society Podcast – A chat with Dr. Benjamin L. Oakes on what CRISPR is, how it revolutionized biological research, and how Scribe Therapeutics will take it to its next generation.

CFOs On the Move

CFO – Biotech firm Scribe Therapeutics appointed David Parrot as chief financial officer. Parrot joins the company from Barclays, where he was a managing director responsible for building its West coast life sciences and biotechnology investment banking business.

CRISPR pioneer’s biotech taps ex-Barclays banker as CFO

CFO Dive – Former Barclays executive David Parrot is bringing a number of lessons learned from his more than two-decade career in life sciences investment banking to his new role as CFO of biotech firm Scribe Therapeutics.

Chutes & Ladders

Fierce Biotech – David Parrot is the new CFO of Scribe Therapeutics, a molecular engineering company focused on CRISPR-based meds, after serving as a managing director at investment bank Barclays.

Peer Review

Endpoints News – One of Jennifer Doudna’s CRISPR startups, Alameda, CA-based Scribe Therapeutics, has corralled David Parrot as CFO and George Manning as controller.

BioSpace Movers & Shakers

BioSpace – Life sciences companies continue to bolster their leadership teams as they prepare for the next phase of growth.

Venture Investment in Crispr Gene Editing Spurs Innovation, Hunt for IP

The Wall Street Journal – Scribe Therapeutics Inc., an Alameda, Calif.-based biotech startup also co-founded by Dr. Doudna, is developing custom-engineered enzymes for Crispr-based treatments for neurodegenerative and other diseases. Scribe’s technologies are distinct from earlier approaches, co-founder and CEO Benjamin Oakes said.

Management Tracks

BioCentury – Scribe Therapeutics Inc. hired David Parrot as CFO. Parrot was managing director, head of west coast life science investment banking at Barclays Investment Bank. Scribe is developing custom enzymes and delivery modalities for CRISPR and was co-founded by Jennifer Doudna.

Appointments and advancements

BioWorld – Scribe Therapeutics Inc., of Alameda, Calif., appointed David Parrot chief financial officer and George Manning controller.

Big Pharma is waking up to the booming field of gene editing. Here are the top 18 biotechs to know in 2022 that are poised to grab the drug industry’s attention.

Business Insider – With a busy 2022 ahead for the gene-editing industry, Insider identified the top 18 companies to know that are leading the space.

Novel Gene Editing Systems Come Into Their Own

Genetic Engineering and Biotechnology News – Scribe scientists hone CasX enzymes so that they acquire characteristics such as enhanced specificity. Oakes describes this as an “engineering first” philosophy, where the desired properties of the system are chosen in advance and intentionally designed, rather than being left to chance or nature.

These gene-editing startups are aiming to solve one of CRISPR’s biggest problems. Here’s how they could upend biotech in 2022.

Business Insider – Scribe’s main enzyme, CasX, is also smaller and more efficient at making edits, Oakes said. This group of companies often searches nature for new enzymes and then tinkers with them in a lab, aiming to make a better editing tool at the end.

California Life Sciences announces 2021 Pantheon Award winners

California Life Sciences – Scribe Therapeutics named Rising Star in the 2021 Pantheon Awards recognizing companies and individuals making significant scientific, business, and community contributions across California.

Biocom Catalyst Awards

Biocom California – Scribe Therapeutics CEO Benjamin Oakes selected as a winner of the 6th annual Catalyst Awards.

Meet the 30 young leaders forging a new future for the healthcare industry in 2021

Business Insider – Scribe CEO Benjamin Oakes is carving out a space in the gene-editing field by developing what he calls a “genetic scalpel.”

Meet the 12 biotechs pioneering cutting-edge cures that stand to upend how we treat diseases and transform pharma

Business Insider – Cofounded by CRISPR discoverer Jennifer Doudna and two former researchers in her University of California lab, Scribe is pursuing its own twist on CRISPR. While the standard gene-editing approach uses an enzyme called Cas9, Scribe is developing a smaller version called CasX, which could allow for more applications of CRISPR.

MedTech Breakthrough Awards: 2021 Winners

MedTech Breakthrough Awards – Scribe Therapeutics wins Best New Technology Solution – Drug Development.

World Changing Ideas Awards 2021: Health Finalists and Honorable Mentions

Fast Company – Medical innovations that save lives, extend longevity, or increase access to care.

Big Money for Gene Editing, Engineering, Structure-Based Drug Design, and Data Management

Bio-IT World – $100M: Series B for Custom Gene Editing. The capital will be used to further develop Scribe’s suite of custom gene editing and delivery technologies, as well as to advance a pipeline of therapeutics for neurodegeneration and additional diseases with high unmet need.

5 Novel Therapies Using Synthetic Biology

Nanalyze – The company has raised a whopping $120 million from the likes of Andreessen Horowitz to build out a suite of CRISPR technologies designed to treat genetic diseases.

Engineering CRISPR with Ben Oakes

a16z Bio Clubhouse – a16z general partners Vineeta Agarwala and Vijay Pande talk to guest Ben Oakes, cofounder, President and CEO of Scribe Therapeutics in a conversation on the power of engineering gene editors, the transition from academia to a startup, and how to select the first indication to target with a novel bio platform.

The 20(+1) under 40: Inside the next generation of biotech leaders

Endpoints News – The annual 20 Under 40 list features CEO Benjamin Oakes and how his dive inside the human mind colors his leadership role at gene editing startup Scribe Therapeutics.

Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline

PMLiVE – Scribe’s technology platform can create custom CRISPR molecules that are specifically designed for therapeutic use within the body, overcoming the limitation of using existing enzymes that may lead to ‘poor editing outcomes’.

Scribe, Jennifer Doudna’s newest startup, nabs a mega-round and a vocal investor

Endpoints News – The California-based biotech will use that cash to continue developing their engineering platform, while bringing forward a pipeline that includes a Biogen-partnered ALS treatment.

CasX start-up Scribe Therapeutics raises $100 million for CRISPR therapies

Chemical & Engineering News – The start-up is applying protein engineering to create new CasX enzymes for neurodegenerative diseases and more.

Scribe Therapeutics snags $100M for engineered CRISPR tech, pipeline

FierceBiotech – Rather than “shoehorning” enzymes that evolved to work well in bacteria—but not in humans—into treatments for human disease, Scribe is engineering CRISPR molecules from scratch.

A New Approach To Crispr – Scribe Therapeutics Designs Novel Crispr Molecules

Forbes – Instead of relying on wild-type or naturally occurring Crispr molecules such as Cas9, Scribe Therapeutics have built their own, highly-specialized varieties.

Scribe Therapeutics Closes Series B Round With $100M To Target Gene Editing

Crunchbase News – Molecular engineering company Scribe Therapeutics has completed an oversubscribed $100 million round of Series B financing to further develop its “CRISPR by design” platform, as well as advance its pipeline of genetic treatments.

Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B

Genetic Engineering & Biotechnology News – Scribe—one of a new wave of gene editing biotech companies—focuses on developing CRISPR-based treatments through its genetic modification platform, designed to build and apply its suite of CRISPR technologies designed for therapeutic use.

Scribe closes $100M series B round for gene editing rewrite

BioWorld – Scribe Therapeutics Inc. raised $100 million in a series B round to continue its engineering-intensive approach to developing CRISPR-based therapies that employ custom-designed CasX enzymes.

Engineering the Future of Genetic Medicine

Technology Networks – Scribe Therapeutics co-founder and CEO Benjamin Oakes sat down for an interview on the company’s next steps in “fulfilling the promise of CRISPR” and how it will navigate some of the challenges associated with developing CRISPR-based therapeutics, including efficacy, scale-up and high costs.

Jennifer Doudna’s Scribe Therapeutics lands a $100M Series B to advance CRISPR technology

San Francisco Business Times – The Alameda-based biotech startup will use the fresh capital to expand its team and advance the company’s specialized approach to gene editing in the hopes of creating new treatments for a host of unmet diseases.

With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting Edge

Barron’s – Gene editing is advancing so quickly that next-generation technologies are already on the heels of Crispr-Cas9.

Top Life Sciences Startups to Watch in 2021

BioSpace – The NextGen Bio Class of 2021 is a stellar group of companies that are already making an enormous impact on the industry now and will continue into the future.

2020 Was the Turning Point for CRISPR

Medium – Future Human – Scribe Therapeutics of Alameda, California, is using yet another form of CRISPR dubbed X-editing. Co-founded by CRISPR pioneer and Nobel winner Jennifer Doudna, PhD, the company will use the new gene-editing tool to develop treatments for neurological diseases.

Engineering the Future of Genetic Medicine

The Scientistt Podcast – Benjamin L. Oakes is the Founder and CEO of Scribe Therapeutics, a company rewriting the story of disease and engineering the future of genetic medicine.

Doudna’s Scribe unveils

Nature Biotechnology – Startup Scribe Therapeutics, spun out of Jennifer Doudna’s lab, emerged from stealth on 6 October with a next-generation CRISPR technology, armed with a $20-million series A round and a collaboration with Biogen.

8 Biocom Member Companies Leveraging CRISPR Technology

Biocom – Another of Doudna’s spin-outs, Scribe Therapeutics, just recently announced their plans to build a platform for CRISPR-based genetic medicine to create therapies for diseases like genetically driven ALS. The company’s tools and mission have the potential to dramatically accelerate CRISPR’s applications into the clinical setting.

Interview with Scribe Therapeutics CEO, Benjamin Oakes

CRISPR Medicine News – California-based gene-editing company Scribe Therapeutics recently unveiled its plans to develop the most advanced platform for breakthrough CRISPR-based genetic medicines.

CRISPR-Based ALS Treatment Being Developed by Scribe and Biogen

Genetic Engineering & Biotechnology News – Best known for her pioneering work in the discovery of CRISPR, Jennifer Doudna, PhD, professor at the University of California, Berkeley, doesn’t stop or, it seems, even slow down. As of yesterday morning, Doudna can add “accept Nobel Prize” to her to-do list as she, along with Emmanuelle Charpentier, PhD, was awarded the 2020 Nobel Prize in Chemistry.

Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases

ALS News Today – Founded by the scientists who originally invented CRISPR, Scribe has developed novel, custom-CRISPR tools, using a technology called X-Editing. This advanced gene-editing platform has greater editing activity and higher specificity, meaning that it can edit the target gene with greater precision than other CRISPR tools currently available.

Biogen teams up with gene-editing startup Scribe on ALS programme

pharmaphorum – Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen.

Doudna Spin Out Scribe, Partners with Biogen on CRISPR-Based Treatment for ALS

Clinical OMICs – This week, another Doudna lab spin out, Scribe Therapeutics, came out of stealth mode to announce their plans to build a platform for CRISPR-based genetic medicine with news of a new Biogen collaboration to create therapeutics for genetically-driven ALS.

Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines

Pharmaceutical Business Review – Molecular engineering company Scribe Therapeutics has entered into a research collaboration with Biogen for the development of CRISPR-based genetic medicines for neurological diseases.

Scribe Therapeutics emerges with $20M, Biogen pact to clear CRISPR hurdles

FierceBiotech – CRISPR evolved in bacteria as a form of “genetic vandalism,” as George Church, Ph.D., puts it, to fend off pathogens. That means it works very well in bacteria but runs into various obstacles when researchers try to put it to work in humans. Jennifer Doudna’s latest CRISPR company plans to surmount those hurdles with an entirely new CRISPR platform that does not rely on molecules found in nature.

Starting with Biogen deal in ALS, Scribe planning a new chapter in CRISPR story

BioWorld – Scribe Therapeutics Inc., another CRISPR-based genome editing firm out of the Jennifer Doudna stable, launched with $20 million in series A funding and a deal with Biogen Inc. in amyotrophic lateral sclerosis (ALS), which brings in another $15 million up front and up to $400 million in development and commercial milestones.

Scribe: engineering CRISPR’s next generation

CRISPR startup Scribe Therapeutics lands big Biogen deal

San Francisco Business Times – Hoping to take the CRISPR genome-editing tool to the next level of drug development, startup Scribe Therapeutics Inc. said Tuesday that it landed a potential $400 million neurodegenerative disease deal with Biogen Inc.

Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter

Xconomy – The first generation of CRISPR-based therapies showed how the technology can edit DNA, making genetic fixes to unwanted mutations. But those treatments use the CRISPR system as scientists found it in nature, which means it still has limitations when applied to humans, says Benjamin Oakes, CEO of Scribe Therapeutics.

Scribe Therapeutics launches to explore next-generation CRISPR technology

Chemical & Engineering News – Scribe Therapeutics, a biotech firm focused on developing next-generation gene-editing technology, has raised $20 million in its first major round of financing, backed by Andreessen Horowitz. The firm separately unveiled a deal with Biogen to develop CRISPR-based treatments for amyotrophic lateral sclerosis (ALS).

The latest Jennifer Doudna startup launches with a Biogen partnership and eyes on big targets few CRISPR companies have chased

Endpoints News – Three years ago, Jennifer Doudna gathered with two postdocs and a fellow biochemist around a circular table on the second floor of UC Berkeley’s energy biosciences building, where they tried to answer a question: What, precisely, would the best gene editor look like?

Doudna Inc.: How Cal scientist created a biotech startup engine

San Francisco Business Times – Jennifer Doudna’s string of companies, including an Alameda startup, have covered everything from agriculture to a Covid diagnostic to potential drugs.

Biogen, gene-editing startup Scribe to develop therapies for Lou Gehrig’s disease

Reuters – U.S. drugmaker Biogen Inc and gene-editing startup Scribe Therapeutics Inc will jointly develop therapies for treating underlying genetic causes of amyotrophic lateral sclerosis (ALS), a fatal neurological disorder better known as Lou Gehrig’s disease.

Scribe Therapeutics launches a platform for engineering CRISPR-based therapeutics

TechCrunch – A new company called Scribe Therapeutics founded by two former members of CRISPR pioneer Jennifer Doudna’s UC Berkely genetics lab (alongside Doudna herself) launched on Tuesday, debuting a platform designed specifically to help develop and engineer new therapeutics based on CRISPR for addressing specific diseases, with permanent treatments in patients.

Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines

Forbes – What if you had a tool to change the genetic instructions that cause disease? That’s what San Francisco-based Scribe Therapeutics hopes to do with its next-generation platform for gene editing.

C&EN’s Year in Pharma 2019

Chemical & Engineering News – Jennifer Doudna’s lab at the University of California, Berkeley, published a detailed study on a genetically and structurally distinct CRISPR enzyme called CasX, which makes staggered breaks during its cutting of the DNA double helix.

CRISPR enzyme from groundwater bacteria shows unusual properties

Chemical & Engineering News – CasX, first described in 2016, is smaller than its more famous cousins, Cas9 and Cas12a. This makes it a potentially better candidate for medicinal use as the field turns to viruses to try to get CRISPR systems into the human body.

New Protein Could Deliver Next Gene-Editing Tool

Drug Discovery & Development – While CRISPR Cas9 remains a mainstay in the genomics world, researchers have now found a much smaller protein called CasX that could be used for gene editing.

CRISPR-CasX could be the next small gene-editing enzyme

New Atlas – In new tests, the researchers have found that it is effective at editing the human genome, as well as that of E. coli.

Watch Out CRISPR-Cas9! There’s a New and Smaller Gene Editor

Interesting Engineering – New research is now revealing CasX is a viable alternative to Cas9. The gene editor was sourced from a microbe database found in groundwater and sediment, and it works in both bacteria and human cells.

Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics

Silicon Republic – CRISPR-Cas9 has revolutionised gene editing, but a new variant of the technology may be far superior.

Tiny New CRISPR Protein Could Make Human Gene-Hacking Less Risky

Futurism – Researchers from UC Berkeley have discovered that CasX is capable of editing human cells, and it doesn’t carry with it some of the issues involved in Cas9 editing — potentially putting us one step closer to safely gene-editing humans.